Lucentis® Vial for Wet AMD, DME, and RVO

Lucentis® (ranibizumab) is an intravitreal anti-VEGF medicine used to treat wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and myopic CNV. This page helps you compare options, review dosing basics, and order Lucentis vial with Canadian pricing and US delivery from Canada. If you pay without insurance, you can still check pricing and potential savings.

At CanadianInsulin, orders are filled by licensed Canadian pharmacies after we confirm a valid prescription with your clinic.

What Lucentis® Is and How It Works

Lucentis® is a prescription injection given into the vitreous of the eye by an ophthalmologist. It targets vascular endothelial growth factor A (VEGF-A), a protein that drives abnormal vessel growth and leakage in the retina. By binding VEGF-A, ranibizumab reduces leakage and swelling, helping stabilize or improve vision in conditions like wet AMD and macular edema. We offer clinic-ready vials from Canada that ship to the US.

Lucentis belongs to a class of medicines called anti-VEGF agents. It is widely used in retina clinics and is supported by large clinical trials. Patients are monitored with eye exams and imaging such as OCT to tailor ongoing treatment. You do not self-inject Lucentis; your eye specialist handles preparation, injection, and sterile technique.

For broader background on this condition class, explore products for Age Related Macular Degeneration Amd.

Who Lucentis® Is For

Lucentis is indicated for adults with neovascular (wet) AMD. It is also used for macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. Your retina specialist will confirm candidacy based on a dilated eye exam and imaging. People with active eye or periocular infections should not receive an intravitreal injection until the infection resolves.

Caution is appropriate in those with a history of stroke or recent arterial thromboembolic events. Tell your clinician about pregnancy or plans to become pregnant. Report any eye pain, redness, or changes in vision after any injection promptly. Learn more about the condition in Retinal Vein Occlusion and Diabetic Macular Edema.

Dosage and Usage

Lucentis dosing is determined by the specific retinal condition and follows the official label:

• Wet AMD: 0.5 mg intravitreal injection once monthly initially. After a series of monthly doses, many clinicians consider treat-and-extend or PRN schedules based on exam and OCT findings.
• Macular edema following RVO: 0.5 mg once monthly until vision and anatomy stabilize, with ongoing monitoring and interval adjustments per clinical judgment.
• Diabetic macular edema and diabetic retinopathy: 0.3 mg once monthly is the labeled dose in the US, with adjustments guided by response.
• Myopic CNV: Often treated with 0.5 mg; many patients need fewer injections, though repeat treatment may be required if disease activity recurs.

These injections are administered in a clinic setting with sterile preparation, topical anesthesia, and antisepsis. If you have questions about your personal schedule, defer to your ophthalmologist and the official prescribing information.

Strengths and Forms

Lucentis comes as single-use presentations for intravitreal use. The vial is commonly supplied as 10 mg/mL in a small volume suitable for a single injection after preparation under sterile technique. Prefilled syringes are also available, designed to deliver the labeled 0.3 mg or 0.5 mg dose.

Clinics may choose between the vial and the prefilled syringe based on workflow and preference. If your clinic prefers a ready-to-use format, see Product Lucentis® Prefilled Syringe. Availability can vary by dose and packaging, and country-specific labeling may differ. Your clinician will select the correct dose and presentation.

Missed Dose and Timing

If an injection visit is missed, contact your retina clinic to reschedule promptly. The timing of the next dose depends on disease activity, your most recent exam, and OCT findings. Do not attempt any self-administration. If you develop eye redness, discharge, pain, or new floaters before a planned injection, call your clinic to discuss whether to delay treatment.

Storage and Travel Basics

Lucentis vials and prefilled syringes are refrigerated in clinic stock. Standard labeling calls for refrigerated storage and protection from light. Do not freeze and avoid shaking. Keep the vial in its carton until use. If you are transporting a dose to your clinic, use a cooler with cold packs and keep the product upright in its carton. Avoid excessive heat during travel.

Orders are shipped with appropriate handling from Canada to the US. Cold-chain practices help protect temperature-sensitive medicines in transit.

Benefits

Lucentis helps reduce abnormal retinal vessel leakage and swelling. In wet AMD, it often stabilizes vision and can improve best-corrected visual acuity for many patients. In diabetic macular edema and retinal vein occlusion, reduced macular thickness often translates into better vision and function. For myopic CNV, some patients require only a small number of injections.

Clinic-administered dosing allows your specialist to assess response at each visit and adjust intervals. The availability of both vial and prefilled syringe options supports a range of clinic workflows.

Side Effects and Safety

• Common local effects: eye pain or discomfort, conjunctival hemorrhage, floaters, mild inflammation, and transient increased intraocular pressure.
• Other expected findings: tearing, light sensitivity, eyelid irritation, and temporary blurred vision after the procedure.

Serious but uncommon risks include endophthalmitis (intraocular infection), retinal detachment, traumatic cataract, sustained intraocular pressure rise, and arterial thromboembolic events. Seek urgent care for severe eye pain, vision loss, increasing redness, or heavy floaters after an injection. Your clinic will use antisepsis and sterile technique to lower infection risk.

For a deeper overview, you can review Lucentis Uses Side Effects Dosage.

Drug Interactions and Cautions

Systemic exposure to ranibizumab is low after intravitreal dosing. Nonetheless, inform your clinician about all medicines and supplements. Caution may be warranted in patients with recent stroke or TIA. Active ocular or periocular infection is a contraindication to injection until treated. Tell your clinician about anticoagulant use, bleeding disorders, uncontrolled glaucoma, or recent ocular surgery. Do not use if the solution appears cloudy, discolored, or contains particulate matter.

What to Expect Over Time

Many patients see early improvements after initial monthly injections, followed by maintenance dosing tailored to OCT and visual outcomes. Some conditions require long-term regular treatment to keep fluid controlled. Your clinician may extend intervals if the macula stays dry, or shorten them if fluid returns. Regular monitoring and adherence to follow-up visits support the best chance of maintaining vision.

Compare With Alternatives

Other anti-VEGF options may be appropriate depending on diagnosis, response, and clinic preference. Aflibercept is a widely used alternative; see Eylea®. Another option is brolucizumab; see Beovu® Pre Filled Syringe. Your specialist will recommend a plan that fits your condition and treatment goals.

Pricing and Access

Check current Lucentis vial pricing from Canada and compare to typical US costs. Ordering through our service provides Canadian pricing with US shipping. If you are exploring ways to stretch your budget, read How To Save On Monthly Lucentis Vial Orders From Canada. Start a request to see your options and any available package sizes. Savings vary by dose and quantity.

Availability and Substitutions

Availability can change by package and dose. If a specific vial or syringe presentation is unavailable, your prescriber may choose a suitable alternative or adjust to a different presentation. We cannot promise restock dates. Your clinic will guide substitutions based on safety, efficacy, and access.

Patient Suitability and Cost Saving Tips

Patients with confirmed wet AMD, DME, DR, RVO, or myopic CNV may be candidates if no active eye infections are present. Those with recent stroke or major cardiovascular events should discuss risks and benefits carefully. Pregnant or breastfeeding patients should consult their clinician before treatment. Lucentis is not for self-use at home.

Ways to manage costs include planning multi-vial orders for clinic use when appropriate, scheduling follow-ups to avoid missed doses, and setting refill reminders so your clinic stock is ready before your next visit. Keep your prescription and clinician contact details handy to streamline verification.

Questions to Ask Your Clinician

• Which dose is right for my condition, 0.3 mg or 0.5 mg?
• How many monthly injections might I need before extending intervals?
• What OCT findings will guide my dosing schedule?
• What are signs of endophthalmitis I should watch for after injection?
• How does Lucentis compare with other anti-VEGF options for me?
• Can I switch between vial and prefilled syringe if needed?
• What precautions should I follow the day of my injection?

Authoritative Sources

• Genentech Lucentis Prescribing Information
• FDA DailyMed: Lucentis
• Health Canada Drug Product Database: Ranibizumab

Ready to proceed? Start your request for US delivery from Canada today. This information is not a substitute for medical advice. Always follow your clinician’s instructions and the official label.